JPS58225074A - Dibenzoazepine derivative - Google Patents

Dibenzoazepine derivative

Info

Publication number
JPS58225074A
JPS58225074A JP10851682A JP10851682A JPS58225074A JP S58225074 A JPS58225074 A JP S58225074A JP 10851682 A JP10851682 A JP 10851682A JP 10851682 A JP10851682 A JP 10851682A JP S58225074 A JPS58225074 A JP S58225074A
Authority
JP
Japan
Prior art keywords
formula
compound
group
lower alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP10851682A
Other languages
Japanese (ja)
Other versions
JPH0359068B2 (en
Inventor
Kiyohiko Ito
伊東 清彦
Masuo Koizumi
小泉 益男
Yasushi Murakami
泰 村上
Hidekazu Hoshino
英一 星野
Tamotsu Yamazaki
保 山崎
Kazunari Sakai
境 一成
Shunichi Hata
畑 俊一
Yoshio Takagaki
高垣 善男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP10851682A priority Critical patent/JPS58225074A/en
Publication of JPS58225074A publication Critical patent/JPS58225074A/en
Publication of JPH0359068B2 publication Critical patent/JPH0359068B2/ja
Granted legal-status Critical Current

Links

Abstract

NEW MATERIAL:The compound of formula I [R<1> is H or one or more substituent groups (halogen, lower alkykoxy or lower alkyl); the group of formula II is group of formula III (R<4> and R<5> are lower alkyl or form together with N a heterocyclic group; m is 2 or 3), 4-methylpiperazinyl or 4-methylhomopiperazinyl] and its salt. EXAMPLE:2, 4-Diisopropyldibenz[b, f][1, 4]oxazepin-11(10H)one-8-carboxylic acid N-methylpiperazinamide. USE:Antiulcer agent. PROCESS:The compound of formula I can be prepared easily by reacting the dibenzoxazepinonecarboxylic acid of formula IV or its reactive derivative (e.g. acid halide, and anhydride, ester, etc.) with the compound of formula V.

Description

【発明の詳細な説明】 本発明は次の一般式 (式中、R1は水素原子又はハロゲン原子、低級アルコ
キシ基、低級アルキル基から選ばれる1〜N<R5,4
−メfルピペラジニル、4−メチルホモピペラジニル基
金意味し、R及びRはそれぞれ低級アルキル基ヌは互に
結合して窒素原子と共に複素りを形成してもよく、mは
2〜3’e示す)で表わされる化合ftt+及びその塩
に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the following general formula (wherein R1 is a hydrogen atom, a halogen atom, a lower alkoxy group, a lower alkyl group).
- methylpiperazinyl, 4-methylhomopiperazinyl group, R and R are lower alkyl groups, respectively, and may be bonded to each other to form a complex with a nitrogen atom, and m is 2 to 3'e ftt+ and its salts.

上式で表わされる本発明の化合物は、例えば、一般式 (式中R′は前記と同一の意味を有する)で表わされる
ジペンゾオキサゼピノンカルボン酸は前記と同一の意味
を有する)の化合物とを反応させることによシ答易に得
られる。ここでいう反応性該導体としては、酸ハライド
、酸無水物またはエステルなどがあげられる。
The compound of the present invention represented by the above formula is, for example, a compound of the general formula (in which R' has the same meaning as above), in which dipenzoxazepinonecarboxylic acid has the same meaning as above). It can be easily obtained by reacting with a compound. Examples of the reactive conductor here include acid halides, acid anhydrides, and esters.

この反応は熱溶媒ヌはアセトン、ベンゼン、テトラヒド
ロフラン、ジオキツン、クロロホルム。
This reaction uses acetone, benzene, tetrahydrofuran, dioxin, and chloroform as thermal solvents.

F[エチル、N、N−ジメチルホルムアミドなどの溶媒
あるいは水など又はその混合物中において、態で使用す
る場合には、脱水剤あるいは縮合剤の存在下で、酸ハラ
イドの状態で使用する場合には、脱ハロゲン化水素剤の
存在下または非存在下で、冷却下、室温あるいは加熱す
ることによシ行う。
F [When used in a solvent such as ethyl, N, N-dimethylformamide, water, etc., or in a mixture thereof, in the presence of a dehydrating agent or a condensing agent, or in the acid halide state, , in the presence or absence of a dehydrohalogenating agent, under cooling, at room temperature, or by heating.

ここでいう脱水剤としては、たとえばN、N’−ジシク
ロへキシルカルボジイミドのようなカルボジイミドが、
縮合剤としては、たとえばオキシ塩化燐。
Examples of the dehydrating agent here include carbodiimides such as N,N'-dicyclohexylcarbodiimide,
Examples of condensing agents include phosphorus oxychloride.

塩化チオニル、ホスゲンなどが、また脱ハロゲン化水素
剤としては、たとえば炭酸水素ナトリウム。
Thionyl chloride, phosgene, etc., and dehydrohalogenation agents include, for example, sodium hydrogen carbonate.

炭酸水素カリウム、炭酸ナトリウム、炭酸カリウム、水
酸化ナトリウム、トリエチルアミン、ピリジンなどを使
用するのが好適である0反応時間は主に反応温度、使用
される試薬の種類によって異なるが瞬時ないし10時間
位である。
It is preferable to use potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, triethylamine, pyridine, etc.The reaction time varies mainly depending on the reaction temperature and the type of reagent used, but it is instantaneous to about 10 hours. be.

かくして得られる本発明の化合物は優れた抗潰瘍作用を
有し医薬として有用である。
The compound of the present invention thus obtained has excellent antiulcer activity and is useful as a medicine.

実施例1゜ 8−カルボキシ−2,4−ジイソプロピルジペンゾ(b
、f〕[1,4)オキサゼピン−11(IOH)オン3
.4tf乾燥ベンゼン25rIleに溶か゛し、これに
チオニルクロライド10m1’i加え3時間還流する。
Example 1 8-carboxy-2,4-diisopropyldipenzo (b
, f] [1,4) Oxazepine-11 (IOH) on 3
.. 4tf was dissolved in 25ml of dry benzene, and 10ml of thionyl chloride was added thereto and refluxed for 3 hours.

反応稜、過剰のチオニルクロリド’tM圧下留去すると
、カルボン酸クロライドが油状残渣として得られる。こ
れをクロロホルム30meに溶かし、N−メチルビペラ
ジン3vと10%NaOH15*eの氷冷混合物へ攪拌
しながら滴加する。水冷下1時間そして、室温にて2時
間攪拌し、クロロホルム層を水洗4回行い、芒硝乾燥稜
溶媒を留去して、2.4−ジイソプロピルジペンゾ(b
、f)[1,4]オキサゼピン−11(IOH)オン8
−カルボン酸N−メチルピペラジンアミド3.6 f 
’Iz得る。収率85.4%、ベンゼンーヘキザンから
再結晶し融点191〜2℃。10%エタノール塩酸から
融点285〜8℃(分解)の塩酸塩を得る。
After the reaction, the excess thionyl chloride 'tM is distilled off under pressure to give the carboxylic acid chloride as an oily residue. This is dissolved in 30me of chloroform and added dropwise with stirring to an ice-cold mixture of 3v of N-methylbiperazine and 10% NaOH15*e. The chloroform layer was stirred for 1 hour under water cooling and then for 2 hours at room temperature, the chloroform layer was washed with water 4 times, the dry ridge solvent was distilled off, and 2,4-diisopropyldipenzo (b
, f) [1,4]oxazepine-11 (IOH) on 8
-Carboxylic acid N-methylpiperazine amide 3.6 f
'Iz get it. Yield 85.4%, recrystallized from benzene-hexane, melting point 191-2°C. A hydrochloride salt having a melting point of 285-8°C (decomposition) is obtained from 10% ethanol hydrochloric acid.

元素分析値 分子式026H3103N3としてOHN 理論値(3)  71.23 7.41 9.97実測
値に)  71.21 7.39 9.85実施例2゜ 8−カルボキシジペンゾ(b、r)(1,t)オキサゼ
ピ:/−11(IOH)オン2.0 ? ’fr:乾燥
N、N−ジメチルホルムアミド35dに溶がし、トリエ
チルアミン1.1 rnlを加え、これにクロル炭酸エ
チルエステル0.94f’i−7℃で滴加する0次いで
N−メチルピペラジン0.8 mef −5℃以下で添
加し、0℃で1時間帽拌する。室綽9−夜放置した抜水
200m1に投入し、析出物をクロロ;ULAr−萱0
..”留J÷〜 去し残ffi ’eシリカゲルクロマトグラフィーに付
す。
Elemental analysis value OHN as molecular formula 026H3103N3 Theoretical value (3) 71.23 7.41 9.97 Actual value) 71.21 7.39 9.85 Example 2゜8-Carboxydipenzo (b, r) ( 1,t) Oxazepi:/-11(IOH)on 2.0? 'fr: Dissolve in 35d of dry N,N-dimethylformamide, add 1.1 rnl of triethylamine, add 0.94f'i of ethyl chlorocarbonate dropwise at -7°C, then add 0.94f'i of N-methylpiperazine. Add 8 mef below -5°C and stir at 0°C for 1 hour. Muroya 9 - Pour into 200ml of drained water that was left overnight, and remove the precipitate with chloro; ULAr - 0
.. .. The residue is subjected to silica gel chromatography.

2%メタノール−クロロホルムで溶出しジペンゾ(b、
r)(x、4)オキサゼピ/−11(IOH)オンケル
ボン酸N−メチルピペラジンアミトヘゴ92得る。収率
28.7%、ベンゼン−ヘキサンから再結晶し融点20
1〜2℃、以稜、実施例1と同様にして塩酸塩を得る。
Dipenzo (b,
r) (x,4)Oxazepi/-11(IOH)oncerboxylic acid N-methylpiperazine amitohego 92 is obtained. Yield 28.7%, recrystallized from benzene-hexane, melting point 20
A hydrochloride salt is obtained in the same manner as in Example 1 at 1-2°C.

融点251℃(分解)。Melting point: 251°C (decomposed).

元素分析値 分子式019I(IJO3N3としてOH
N 理論値(1) 67.46 5.68 12.46実測
値に) 67.52 5.58 12.35実施例3〜
10゜ 実施例1又は実施例2と同様にして表Iの化合第1頁の
続き Q多発 明 者 山崎保 東京都豊島区高田三丁目41番8 号中外製薬株式会社内 0発 明 者 境−成 東京都豊島区高田三丁目41番8 号中外製薬株式会社内 0発 明 者 畑俊− 東京都豊島区高田三丁目41番8 号中外製薬株式会社内 0発 明 者 高垣善男 東京都豊島区高田三丁目41番8 号中外製薬株式会社内
Elemental analysis value Molecular formula 019I (OH as IJO3N3
N Theoretical value (1) 67.46 5.68 12.46 Actual value) 67.52 5.58 12.35 Example 3~
10゜ Compounds of Table I in the same manner as in Example 1 or Example 2 Continued from page 1 of Q Multiple Examples Author: Tamotsu Yamazaki Chugai Pharmaceutical Co., Ltd., 3-41-8 Takada, Toshima-ku, Tokyo 0 Inventor: Sakai - Chugai Pharmaceutical Co., Ltd., 3-41-8 Takada, Toshima-ku, Tokyo Inventor: Toshi Hata - Chugai Pharmaceutical Co., Ltd., 3-41-8 Takada, Toshima-ku, Tokyo Inventor: Yoshio Takagaki Toshima-ku, Tokyo 3-41-8 Takada Chugai Pharmaceutical Co., Ltd.

Claims (1)

【特許請求の範囲】 一般式 (式中、R1は水素原子又はハロゲン原子、低級アルコ
キシ基、低級アルキル基から選ばれる1〜ピペラジニル
基を意味し、R4及びFLSはそれぞれ低級アルキル基
又は互に結合して窒素原子と共に複素環を形成してもよ
く、惟は2〜3を示す)で表わされる化合物及びその塩
[Claims] General formula (wherein R1 means 1 to piperazinyl group selected from a hydrogen atom or a halogen atom, a lower alkoxy group, a lower alkyl group, and R4 and FLS are each a lower alkyl group or a bond with each other) may form a heterocycle together with a nitrogen atom, and the compound represented by the formula (2 or 3) and its salt.
JP10851682A 1982-06-25 1982-06-25 Dibenzoazepine derivative Granted JPS58225074A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10851682A JPS58225074A (en) 1982-06-25 1982-06-25 Dibenzoazepine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10851682A JPS58225074A (en) 1982-06-25 1982-06-25 Dibenzoazepine derivative

Publications (2)

Publication Number Publication Date
JPS58225074A true JPS58225074A (en) 1983-12-27
JPH0359068B2 JPH0359068B2 (en) 1991-09-09

Family

ID=14486768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10851682A Granted JPS58225074A (en) 1982-06-25 1982-06-25 Dibenzoazepine derivative

Country Status (1)

Country Link
JP (1) JPS58225074A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183936B2 (en) 2014-03-13 2019-01-22 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
US10377748B2 (en) 2015-09-15 2019-08-13 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11040965B2 (en) 2017-03-13 2021-06-22 Assembly Biosciences, Inc. Process for making Hepatitis B core protein modulators
US11078170B2 (en) 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
US11649218B2 (en) * 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183936B2 (en) 2014-03-13 2019-01-22 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
AU2015229174B2 (en) * 2014-03-13 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein allosteric modulators
US10947224B2 (en) 2014-03-13 2021-03-16 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
US10377748B2 (en) 2015-09-15 2019-08-13 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10392379B2 (en) 2015-09-15 2019-08-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10766890B2 (en) 2015-09-15 2020-09-08 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10968211B2 (en) 2015-09-15 2021-04-06 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11814376B2 (en) 2015-09-15 2023-11-14 Assembly Biosciences, Inc. Hepatitis b core protein modulators
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11078170B2 (en) 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
US11040965B2 (en) 2017-03-13 2021-06-22 Assembly Biosciences, Inc. Process for making Hepatitis B core protein modulators
US11649218B2 (en) * 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Also Published As

Publication number Publication date
JPH0359068B2 (en) 1991-09-09

Similar Documents

Publication Publication Date Title
CA1334972C (en) Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds
EP0249950B1 (en) Aromatic compounds
EP0030009B1 (en) New derivatives of the 9-cis-6,6&#39;-diapo-psi,psi-carotenedioic acid, preparation thereof and pharmaceutical compositions containing same
JPS58225074A (en) Dibenzoazepine derivative
US3751447A (en) Novel guanidinocaproic acid phenyl esters and their production
WO1983000044A1 (en) Novel aminosulfonylbenzoic acid derivatives and process for their preparation
JPS60231651A (en) Manufacture of pyrrolidone derivative
HU182257B (en) Process for producing benzothiazole derivatives and pharmaceutical compositions containing them as active agents
JPH0361667B2 (en)
US3875173A (en) Method for introducing halogen into benzimidazole and imidazopyridine compounds
SU505369A3 (en) The method of obtaining the esters of 1-imidazolylmethanephosphonic acid
SU639450A3 (en) Method of obtaining heterogeneous ring compounds or salts thereof
JPS591714B2 (en) Process for producing isothiazoloisoquinoline derivatives
US2524802A (en) Hydroxybenzenesulfonamidopyridazines and preparation of same
JPS606954B2 (en) Method for producing 1-(2-tetrahydrofuryl)-3-substituted-5-fluorouracil
JPH03110553A (en) Production of amidophenols
JPS6052158B2 (en) Cephalosporin compounds
JPS6136519B2 (en)
JPS58225073A (en) Dibenzoxazepinone derivative
JPS5920668B2 (en) Process for producing quinazoline derivatives
JPS58140065A (en) Mercaptobenzyl fatty acid derivative and its preparation
US3164613A (en) Hydroxybenzothiazoles and methods of preparing same
JPS5810379B2 (en) Dipeptide Ruinoseihou
US3714172A (en) Process for preparing 2-acetamido-3-benzyloxy or 3-benzylthio-pyridides and derivatives thereof
JPH04173780A (en) 3,4-diphenylisoxazole derivative